However, considering the observed enrichment of dysfunctional CD8+ T cell subsets in cirrhotic patients,95 it is plausible to speculate that CD8+ T cell‐based therapy (Figure 4), when applied early in HBV‐induced liver fibrosis and then cirrhosis, might still be effective for disease control. Here, CD8A is linked to Cirrhosis.